Navafenterol is a new compound with both muscarinic receptor antagonist and β2 recep-tor agonist effects in a single molecule,who is be-ing developed for the treatment of chronic obstruc-tive airway disease such as chronic obstructive pul-monary disease and asthma.These pilot clinical studies found that it can significantly improve lung function and symptoms,and is safe and well toler-ated.Common treatment emergent adverse events include headache,nasopharyngitis,and dizziness.It may become a next-generation bronchodilator for chronic obstructive airway disease.This review introduced the prospective of Navafenterol.
维普
万方数据